2003 was an up and down year for proteomics: Academic and clinical researchers made out well — spurred by hefty NIH funding initiatives, instrument vendors courting customers, HUPO’s expansion, and an explosion of interest in proteomics biomarker discovery — while technology start-ups continued to fumble for footing, and large instrument companies merged and reorganized their marketing strategies to stress product integration.
NIH Funding Strong
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
